BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, April 22, 2026
Home » AI

Articles Tagged with ''AI''

Helfie skin cancer

Helfie AI partners with Microsoft to democratize health care

Oct. 30, 2024
By Tamra Sami
Mobile health platform company Helfie AI has partnered with Microsoft to offer Microsoft enterprise customers the ability to license Helfie’s cutting-edge health assessment tools directly through the Microsoft Azure Marketplace.
Read More
Digital cancer cells illustration
Cancer

AI drug developer Aigen Sciences raises ₩12B series A

Oct. 30, 2024
By Marian (YoonJee) Chu
Backed by AI technology, Aigen Sciences Inc. raised ₩12 billion (US$8.8 million) in a series A financing round to further advance its cancer and rare disease drug pipelines. Aigen said Oct. 16 that the series A round was joined by existing investors Partners Investment, Quad Investment Management and Medytox Venture Investment, as well new investors Premier Partners, K2 Investment Partners and Scale Up Partners.
Read More
Pill in immersive interface

BioFuture 2024: Where AI leads, developers must follow

Oct. 28, 2024
By Lee Landenberger
Artificial intelligence (AI) is enabling a foundational understanding of drug discovery that is changing the typical pathway used in modern development. The powerful new computer technology will lead developers from conducting hypothesis-driven research to more and deeper data-driven research, Manolis Kellis, professor at the Computer Science and Artificial Intelligence Laboratory at the Massachusetts Institute of Technology (MIT) and an associate member at the Broad Institute of MIT and Harvard University, told those attending the BioFuture 2024 conference in New York on Oct. 28.
Read More
IR machine learning
Patents

IR spectroscopy, machine learning combine for cancer diagnosis

Oct. 28, 2024
By Simon Kerton
The third PCT family of patenting to emerge from IR Medtek LLC, and its first as the sole named assignee, sees its CEO, Douglas Cohen, continue to build protection for the company’s platform which uses a light detection technology and machine learning to improve the accuracy of cancer diagnosis.
Read More
Lunit INSIGHT MMG

Two more studies for Lunit Insight MMG in breast cancer screening

Oct. 24, 2024
By Marian (YoonJee) Chu
A recent retrospective cohort study of Insight MMG highlighted potential of Lunit Inc.’s artificial intelligence-powered breast cancer screening tool in detecting “subtle signs of cancer” earlier for women.
Read More

AI drug developer Aigen Sciences raises ₩12B series A

Oct. 22, 2024
By Marian (YoonJee) Chu
Backed by AI technology, Aigen Sciences Inc. raised ₩12 billion (US$8.8 million) in a series A financing round to further advance its cancer and rare disease drug pipelines.
Read More
Michelle Tarver, FDA device center director
Med Tech Conference 2024

Shuren confirms Tarver in as FDA’s device center director

Oct. 18, 2024
By Mark McCarty
The speculation as to the status of Michelle Tarver, the acting director of the U.S. FDA’s device center, is officially over despite disclaimers at. The outgoing director, Jeff Shuren, said Tarver “will make a great center director” in remarks during an Oct. 17 public appearance, thus cementing Tarver’s role at FDA.
Read More

AI drug developer Aigen Sciences raises ₩12B series A

Oct. 16, 2024
By Marian (YoonJee) Chu
Backed by AI technology, Aigen Sciences Inc. raised ₩12 billion (US$8.8 million) in a series A financing round to further advance its cancer and rare disease drug pipelines.
Read More
Echo IQ Echosolv

FDA clears 510(k) for Echo IQ’s aortic stenosis SaMD

Oct. 9, 2024
By Tamra Sami
The U.S. FDA gave the 510(k) green light to Echo IQ Ltd.’s Echosolv AS for its AI-enabled software as a medical device to be used as a decision support aid in detecting severe aortic stenosis.
Read More
Illustration of 2024 Nobel Prize in Physics winners John Hopfield and Geoffrey Hinton
Drug design, drug delivery & technologies

2024 Physics Nobel goes for foundations of AI

Oct. 9, 2024
By Anette Breindl
It’s hard to know where to start in describing the biopharma applications of the 2024 Nobel Prize in Physics. It was awarded to John Hopfield and Geoffrey Hinton “for foundational discoveries and inventions that enable machine learning with artificial neural networks.”
Read More
Previous 1 2 … 12 13 14 15 16 17 18 19 20 … 50 51 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 22, 2026.
  • Man holding raised arm with illustrated overlay of nerves

    Biohaven reports details on discovery of BHV-2100

    BioWorld Science
    Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
  • Elderly woman holding illustration of brain with missing puzzle piece

    Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’

    BioWorld
    The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
  • New GABA(B) receptor PAMs revealed in Addex Pharma patents

    BioWorld Science
    Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
  • MMP inhibitors divulged in Accure Therapeutics patent

    BioWorld Science
    Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing